Blood
Articles in this Issue
Overcoming midostaurin resistance via dual MYC and GSPT1 degradation by the protac GT19715 in FLT3-amplified AML cells
Abstract In acute myeloid leukemia (AML) carrying FLT3 mutations, resistance to the multikinase inhibitor midostaurin arises via clonal evol...
Double or triple therapy in newly diagnosed immune thrombocytopenia: Improving outcomes from the west-central Mexican experience.
Abstract Introduction Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by a low platelet c...
Murine regulatory NK cells restrict allogeneic CD4⁺ T cell-driven gvhd without compromising cytotoxic function
Abstract Suppression of alloreactive responses is a major limitation to current therapies for graft-versus-host disease (GVHD), as they broa...
Outcomes following lower-intensity therapy with venetoclax in patients with NPM1-mutated Acute Myeloid Leukemia are highly dependent upon co-occurring mutations
Abstract Background Mutated nucleophosmin-1 (NPM1m) is present in ~ 30% of patients (pts) with newly-diagnosed acute myeloid leukemia (ND-AM...
Improved survival after post-transplant relapse of adult t-cell leukemia-lymphoma and trends of salvage therapy
Abstract Introduction Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers potentially curative outcomes for adult T-cell l...
Comparative use of complex innovative trial designs in hematologic vs solid tumors: A cross-sectional study of clinicaltrials.gov (2015–2023)
Abstract Background Complex innovative trial designs (CIDs) have gained prominence in recent years as a means to enhance efficiency and flex...
Avatrombopag: Beyond efficacy
Abstract INTRODUCTION Thrombopoietin Agonists (TPO-AR) are the treatment of choice in 2nd line in ITP. There are different agonists that act...
Machine learning–driven prognostication of overall survival at 6 months after CAR-T cell therapy
Abstract Background Chimeric-antigen-receptor (CAR) T-cell therapy has transformed outcomes for relapsed or refractory hematologic malignanc...
Thiopurine pharmacogenomic landscape in India: TPMT and NUDT15 allele frequencies
Abstract Thiopurines—such as azathioprine, mercaptopurine, and thioguanine—are commonly used in hematology as immunosuppressants and chemoth...
Disruption of NAD⁺ and gsh/GPX4 axis via NAMPT inhibition by elaiophylin sensitizes AML to ferroptosis
Abstract Objective Acute myeloid leukemia (AML) is a highly heterogeneous and aggressive hematologic malignancy, with therapeutic outcomes fr...
Response-adapted Phase 2 study of acalabrutinib window prior to frontline chemotherapy in untreated large B-cell lymphoma: Molecular correlates of response to acalabrutinib
Abstract Background: Large B-cell lymphoma (LBCL) is characterized by genetic heterogeneity that confers a differential response to therapy....
Real-world evaluation of ctdna for risk stratification across the spectrum of both aggressive and indolent lymphomas
Abstract Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for treatment response monitoring, risk stratifica...
Acute leukemia during pregnancy: A three-decade Mayo Clinic experience
Abstract Introduction Management of acute leukemia (AL) during pregnancy remains challenging. In the first trimester, chemotherapy is toxic...
A comparison of intravenous iron formulations for treating iron deficiency anemia after bariatric surgery
Abstract Background: Iron deficiency (ID) is common following bariatric procedures and frequently leads to anemia. While...
Comparative performance of khorana, padua, and improve-VTE risk assessment models for venous thromboembolism risk stratification in hospitalized oncology patients
Abstract Background: Venous thromboembolism (VTE) occurs in up to 8% of patients with cancer and is associated with increased morbidity and...
“efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin for recurrent VTE in cancer patients: A grade-assessed comprehensive meta-analysis of expanded outcomes from randomized controlled trials.”
Abstract Background: Venous thromboembolism (VTE) is a significant clinical complication in oncology, with a high prevalence among cancer pa...
Real-world study on discontinuation strategies after MRD negativity in multiple myeloma patients
Abstract Background Multiple myeloma (MM) is a malignant clonal plasma cell disorder characterized by uncontrolled proliferation of abnormal...
INCB160058 selectively targets JAK2V617F-driven hematopoiesis in diverse and drug-resistant models of myeloproliferative neoplasms
Abstract INCB160058 is a first-in-class, orally bioavailable Janus kinase 2 (JAK2) V617F mutant-selective inhibitor, currently being studied...
Encouraging long-term efficacy and safety from first-in-human phase 1 study of time-limited NVG-111 in relapsed/refractory CLL and MCL
Abstract Background: Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a validated therapeutic target in haematologic malignancies,...
Efficacy and safety of nivolumab-based therapies in first-line and Relapsed/Refractory Hodgkin lymphoma
Abstract Introduction: Despite being considered one of the most curable cancers, a sizable percentage of individuals wit...
Comparative clinical outcomes of offspring versus matched sibling donor hematopoietic stem cell transplantation in adults aged over 40 years with acute leukemia or Myelodysplastic Syndromes
Abstract Background: With advancing safety profiles in allogeneic hematopoietic stem cell transplantation (allo-HSCT), whether HLA-matched s...
Response to TFPI-inhibition in severe factor v deficiency with a novel compound heterozygous mutation
Abstract Introduction Coagulation factor V (FV) plays a central role in blood clot formation. FV has both procoagulant and anticoagulant pro...
Impact of novel genetic variants in HYOU1 on neutrophil phenotype
Abstract Neutrophils, the most abundant leukocytes in the innate immune system, are crucial for defending against pathogens at the frontline...
Impact-AL: A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis
Abstract Background and Significance: Systemic immunoglobulin light chain (AL) amyloidosis remains a challenging disease, with current front...
Post-transplant FLT3 inhibitor maintenance is associated with improved survival in FLT3-ITD positive acute myelogenous leukemia irrespective of pre-transplant MRD status
Abstract Introduction: Acute myeloid leukemia (AML) with FLT3-internal tandem duplication (ITD) mutations represent ~25% of all AML cases an...